从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），2024年东方生物的俞锦洪薪酬降幅最大，同 比降幅达30.36%；透景生命的李松涛薪酬增幅最大，同比涨幅达70.65%。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 责任编辑：公司观察 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 从薪酬分布看，A股体外诊断公司CFO年薪平均值为84.47万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为10%、76%、10%、4%。 其中，年薪排行前三的CFO分别为新产业的丁晨柳、万孚生物的余芳霞、科华生物的罗芳，三人年薪分 别为284万元、178.17万元、161.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有29家上市体外诊断公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，4 ...

从薪酬分布看，A股体外诊断公司CFO年薪平均值为84.47万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为10%、76%、10%、4%。 其中，年薪排行前三的CFO分别为新产业的丁晨柳、万孚生物的余芳霞、科华生物的罗芳，三人年薪分 别为284万元、178.17万元、161.48万元。 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有29家上市体外诊断公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到66%；50岁以上的CFO占比 为34%。其中，目前仍任职的最年轻的上市公司CFO年龄41岁，为硕世生物的孟元元。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为4%、52%、41%、3%。其 中，获得博士学历的CF ...

Core Insights - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The CFO age distribution shows that 66% are aged between 40 and 50, while 34% are over 50 [1] - The educational background of CFOs indicates that 52% hold a bachelor's degree, 41% a master's degree, and only 3% a doctoral degree [1] Salary Distribution - The average annual salary for CFOs in the A-share diagnostic companies is 844,700 yuan [1] - Salary distribution reveals that 10% earn below 500,000 yuan, 76% earn between 500,000 and 1 million yuan, 10% earn between 1 million and 2 million yuan, and 4% earn above 2 million yuan [1] - The top three highest-paid CFOs are Ding Chenliu from New Industry at 2.84 million yuan, Yu Fangxia from Wanfu Biology at 1.78 million yuan, and Luo Fang from Kehua Biology at 1.61 million yuan [2] Salary Changes - The largest salary decrease was observed for Yu Jinhong from Dongfang Biology, with a year-on-year decline of 30.36% [2] - The highest salary increase was recorded for Li Songtao from Tengkang Life, with a year-on-year increase of 70.65% [2]

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][6] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [6] Group 3: Company Initiatives in Diagnostics and Treatment - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [4][5] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can provide comprehensive genomic analysis within 6-8 hours, aiding in rapid response to the outbreak [4] - Wanfu Biology has developed multiple Chikungunya virus detection products, creating a closed-loop system for monitoring and diagnosis [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing symptoms like fever and joint pain [6][7] - Companies such as Guangdong Yifang Pharmaceutical and Step Long Pharmaceutical are producing traditional Chinese medicines that may assist in treating Chikungunya fever [7]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Wanfu Biological, indicating a decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - As of August 7, Wanfu Biological's stock closed at 24.43 yuan, with a rolling PE ratio of 22.09, marking a new low in 11 days, and a total market capitalization of 11.761 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 54.79, with Wanfu Biological ranking 49th among its peers [1][2] Group 2 - For the first quarter of 2025, Wanfu Biological reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1] - Wanfu Biological specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]

Group 1 - The stock price of Wanfu Biology reached 24.34 yuan as of August 4, 2025, with an increase of 0.45% compared to the previous trading day [1] - The trading volume on that day was 138,900 lots, with a total transaction amount of 332 million yuan [1] - Wanfu Biology operates in the medical device industry, focusing on the research, production, and sales of rapid diagnostic reagents and related instruments [1] Group 2 - The company's product range includes areas such as infectious diseases, chronic diseases, and drug testing [1] - Recently, the company announced the development of multiple detection products for the chikungunya virus, utilizing colloidal gold and molecular diagnostic technology platforms [1] - These products aim to provide reliable monitoring solutions for disease control and inspection at ports [1] Group 3 - On August 4, the net outflow of main funds was 15.71 million yuan, with a cumulative net outflow of 16.24 million yuan over the past five days [1]

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Group 1 - The core point of the article is that Wanfu Biology announced the approval of its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software," marking a significant milestone in the field of cervical cytology with the first AI-assisted diagnosis Class III product registration in the country [1] - The AI-assisted reading of slides significantly enhances diagnostic efficiency and accuracy, providing more precise treatment plans for patients [1] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis and aims to continue innovating in the pathology AI field, promoting the digital transformation of the industry [1]

证券日报网讯万孚生物（300482）7月31日在互动平台回答投资者提问时表示，2025年6月18日，公司召 开第五届董事会第十二次会议，审议通过了《关于终止实施2024年限制性股票激励计划暨回购注销限制 性股票的议案》并已经2025年第一次临时股东大会审议通过，公司结合实际情况，决定终止实施2024年 限制性股票激励计划。 ...

Core Viewpoint - The company has made significant advancements in the AI sector, particularly in the field of cervical cytology, with the approval of an AI-assisted diagnostic software, marking a milestone in digital pathology [2] Company Summary - Wanfu Biology (300482.SZ) announced on July 30 that its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software" has received formal approval, becoming the first AI-assisted diagnostic Class III product registration in the national cervical cytology field [2] - This approval signifies a new milestone for the "Digital Pathology + AI Assistance" model, which enhances diagnostic efficiency and accuracy through AI-assisted slide reading, providing more precise treatment plans for patients [2] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis, and with the company's support, it will continue to deepen its focus on the pathology AI field, driving the development and application of more innovative technologies [2] Industry Summary - The approval of the AI-assisted diagnostic software is expected to contribute to the digital transformation of the pathology industry, providing higher quality and smarter pathology solutions for doctors and patients [2]